Esperion Therapeutics, Inc. (ESPR) Stake Decreased by Tiverton Asset Management LLC

Tiverton Asset Management LLC reduced its holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 24.5% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 16,094 shares of the biopharmaceutical company’s stock after selling 5,231 shares during the quarter. Tiverton Asset Management LLC owned about 0.07% of Esperion Therapeutics worth $745,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the company. BB Biotech AG grew its position in shares of Esperion Therapeutics by 7.6% in the 1st quarter. BB Biotech AG now owns 1,408,542 shares of the biopharmaceutical company’s stock worth $49,736,000 after buying an additional 100,000 shares during the last quarter. FMR LLC grew its position in shares of Esperion Therapeutics by 70.8% in the 1st quarter. FMR LLC now owns 1,308,588 shares of the biopharmaceutical company’s stock worth $46,206,000 after buying an additional 542,579 shares during the last quarter. Boxer Capital LLC bought a new stake in shares of Esperion Therapeutics in the 1st quarter worth approximately $45,020,000. Credit Suisse AG grew its position in shares of Esperion Therapeutics by 26.4% in the 1st quarter. Credit Suisse AG now owns 878,824 shares of the biopharmaceutical company’s stock worth $31,030,000 after buying an additional 183,440 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in shares of Esperion Therapeutics by 20.5% in the 1st quarter. Vanguard Group Inc. now owns 724,150 shares of the biopharmaceutical company’s stock worth $25,569,000 after buying an additional 123,318 shares during the last quarter. Hedge funds and other institutional investors own 83.33% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://sportsperspectives.com/2017/09/17/esperion-therapeutics-inc-espr-stake-decreased-by-tiverton-asset-management-llc.html.

Esperion Therapeutics, Inc. (ESPR) opened at 51.93 on Friday. The stock has a 50 day moving average price of $48.12 and a 200 day moving average price of $40.42. The stock’s market cap is $1.17 billion. Esperion Therapeutics, Inc. has a 1-year low of $9.40 and a 1-year high of $57.38.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) EPS for the quarter, missing the consensus estimate of ($1.67) by ($0.25). During the same quarter in the previous year, the firm posted ($0.62) earnings per share. On average, analysts predict that Esperion Therapeutics, Inc. will post ($7.29) EPS for the current fiscal year.

A number of brokerages have recently weighed in on ESPR. UBS AG reiterated a “buy” rating and issued a $57.00 price objective (up from $52.00) on shares of Esperion Therapeutics in a research report on Tuesday, June 27th. Jefferies Group LLC upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating and lowered their target price for the company from $85.00 to $55.00 in a research note on Tuesday, August 8th. Stifel Nicolaus restated a “buy” rating and issued a $70.00 target price (up previously from $60.00) on shares of Esperion Therapeutics in a research note on Thursday, August 10th. Zacks Investment Research upgraded Esperion Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, August 23rd. Finally, Needham & Company LLC raised their target price on Esperion Therapeutics from $58.00 to $72.00 and gave the company a “positive” rating in a research note on Tuesday, August 8th. Seven equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Esperion Therapeutics has an average rating of “Buy” and a consensus price target of $52.54.

Esperion Therapeutics Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Want to see what other hedge funds are holding ESPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Esperion Therapeutics, Inc. (NASDAQ:ESPR).

Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply